» Articles » PMID: 19076369

Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease

Overview
Specialty Science
Date 2008 Dec 17
PMID 19076369
Citations 234
Authors
Affiliations
Soon will be listed here.
Abstract

Glutamate's role as a neurotransmitter at synapses has been known for 40 years, but glutamate has since been shown to regulate neurogenesis, neurite outgrowth, synaptogenesis, and neuron survival in the developing and adult mammalian nervous system. Cell-surface glutamate receptors are coupled to Ca(2+) influx and release from endoplasmic reticulum stores, which causes rapid (kinase- and protease-mediated) and delayed (transcription-dependent) responses that change the structure and function of neurons. Neurotrophic factors and glutamate interact to regulate developmental and adult neuroplasticity. For example, glutamate stimulates the production of brain-derived neurotrophic factor (BDNF), which, in turn, modifies neuronal glutamate sensitivity, Ca(2+) homeostasis, and plasticity. Neurotrophic factors may modify glutamate signaling directly, by changing the expression of glutamate receptor subunits and Ca(2+)-regulating proteins, and also indirectly by inducing the production of antioxidant enzymes, energy-regulating proteins, and antiapoptotic Bcl-2 family members. Excessive activation of glutamate receptors, under conditions of oxidative and metabolic stress, may contribute to neuronal dysfunction and degeneration in diseases ranging from stroke and Alzheimer's disease to psychiatric disorders. By enhancing neurotrophic factor signaling, environmental factors such as exercise and dietary energy restriction, and chemicals such as antidepressants may optimize glutamatergic signaling and protect against neurological disorders.

Citing Articles

Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.

Dai F, Wengler K, He X, Wang J, Yang J, Parsey R Transl Psychiatry. 2025; 15(1):71.

PMID: 40025010 PMC: 11873289. DOI: 10.1038/s41398-025-03292-9.


Effects of exercise training on the nigrostriatal glutamatergic pathway and receptor interactions in Parkinson's disease: a systematic review.

Ishaq S, Shah I, Lee S, Wu B Front Aging Neurosci. 2025; 17:1512278.

PMID: 40007696 PMC: 11850376. DOI: 10.3389/fnagi.2025.1512278.


Physical Activity and Depression in Breast Cancer Patients: Mechanisms and Therapeutic Potential.

Li A, Zheng X, Liu D, Huang R, Ge H, Cheng L Curr Oncol. 2025; 32(2).

PMID: 39996878 PMC: 11854877. DOI: 10.3390/curroncol32020077.


Brain-derived neurotrophic factor (BDNF) changes in rodent models of schizophrenia induced by ketamine: a systematic review.

Motamedi-Manesh A, Asanjan M, Fallah H, Gharibian S, Taghavi A, Poode Z Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976721 DOI: 10.1007/s00210-025-03912-7.


Monosodium Glutamate Treatment Elevates the Immunoreactivity of GFAP and S100β in Caudate Nucleus of the Striatum in Rats.

Rycerz K, Krawczyk A, Jaworska-Adamu J, Arciszewski M Biomedicines. 2025; 12(12.

PMID: 39767670 PMC: 11672967. DOI: 10.3390/biomedicines12122763.


References
1.
Dirnagl U, Iadecola C, Moskowitz M . Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22(9):391-7. DOI: 10.1016/s0166-2236(99)01401-0. View

2.
Mattson M . Calcium and Free Radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Perspect Dev Neurobiol. 1996; 3(2):79-91. View

3.
Mattson M . Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol. 1992; 27(1):29-49. DOI: 10.1016/0531-5565(92)90027-w. View

4.
Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M . The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl. 2004; (68):117-22. DOI: 10.1007/978-3-7091-0579-5_14. View

5.
Cheng B, Mattson M . IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci. 1992; 12(4):1558-66. PMC: 6575795. View